Latest news with #ResearchandMarkets
Coin Geek
9 hours ago
- Business
- Coin Geek
Indonesia, Thailand digital wallet market record growth in 2025
Getting your Trinity Audio player ready... The Indonesian prepaid card and digital wallet market is expected to grow by nearly 10% in 2025, according to a new report. The report, compiled by Research and Markets, projects an 8.4% growth for the card and digital wallet sector, bringing its market capitalization to $7.94 billion by the end of 2025. While the sector has grown since 2020, analysts from Research and Markets are predicting a continuation of the high metrics up to 2029. The report is eyeing a compound annual growth rate (CAGR) of 6.6% between 2025 and 2029, which is poised to grow the market capitalization to over $10 billion. Between 2020 and 2025, the industry's CAGR stood at 13%, but stiffer regulations and a changing consumer climate may slow industry growth. The biggest driver of growth is massive technological improvement in the Indonesian financial landscape. Prepaid cards can be seamlessly integrated with digital wallets and mobile payment platforms, expanding their utility beyond traditional PoS use cases. With contactless cards going mainstream, prepaid card solutions are racking up wider adoption levels in Indonesia. Furthermore, the e-commerce and ride-hailing sectors are powering the need for prepaid card solutions, while the giant strides in cross-border payments are playing their part in the sector's growth. 'As the adoption of digital payment technologies accelerates, prepaid cards will become an even more essential component of Indonesia's financial ecosystem,' read the report. Analysts at Research and Markets report that closed-loop cards accepted at specific retailers will see their market share growth slow down before the end of the decade. On the other hand, open-loop cards will be the biggest growth driver by card type, with mid-tier businesses leading in terms of business segmentation. The report sheds light on the emerging virtual prepaid card market, predicting that the segment will record a double-digit CAGR in the period under review. In terms of market share, mainstream financial institutions will be the largest cohort, leveraging their customer base and emerging digital banking capabilities. However, the report predicts the rise of new fintech with their suite of innovative prepaid card solutions to snag market share from industry heavyweights. Indonesia braces for changes to its financial ecosystem Players in Indonesia's financial ecosystem are readying themselves for a raft of changes poised to change the local landscape. For starters, the country is transitioning oversight of the digital asset sector to the Financial Services Authority from the Trade Ministry. While the transition is the most seismic in terms of impact, investors are keeping their eye on the commodities watchdog over potential changes to introduce double taxation to digital currencies. Furthermore, the country's central bank is inching forward with its central bank digital currency (CBDC) experiments. Thailand's prepaid card market will clinch an $18.64 billion valuation in 2025 Meanwhile, the prepaid card market in Thailand is growing too and is tipped to achieve an $18.64 billion valuation by the end of 2025. According to another Research and Markets report, the sector's impressive growth rate will continue on its current trajectory till the end of the decade. The report pegs the compound annual growth rate (CAGR) at 13.4%, which will see it reach a peak of $30.87 billion in 2030. Several factors account for the industry's projected growth, including the speed of financial innovation and strong regulatory support from the government. The Southeast Asian country has been advocating for a cashless economy, and prepaid card issuers are angling to reap the rewards of a policy change. Thailand's digital money scheme, designed to provide cash to millions of citizens, is considered a major growth driver for the prepaid card market amid a streak of digital wallet integrations. The report highlights the increasing trend of digital wallet integrations with prepaid cards and their rising utility for expense management by corporate entities. Companies cite the perks of real-time transaction monitoring and the possibility of improving corporate expenditure management. The report predicts a rise in 'customized prepaid card offerings' for corporate finance use cases to broaden access across Thailand. Mainstream commercial banks will continue dominating the industry, given their massive client base and headstart in digital banking. The report lists Bangkok Bank (NASDAQ: BKKLY), Kasikorn Bank, and Siam Commercial Bank as the trio with the largest market share but hints at the rise of new fintech firms. Among the new entrants in the space, TrueMoney, Rabbit LINE Pay, and AirPay are charting a path, offering prepaid card offerings with digital wallet integration and a spate of personalized solutions for consumers. Over the last two years, the local ecosystem has been dotted with a streak of partnerships and new launches from new entrants in the space, but larger players are also snapping up emerging firms in high-profile acquisitions. A changing financial landscape Thai authorities are leaning on digital assets to improve the sector, famously turning to digital currencies as electronic cash in Phuket. Thai authorities are also pushing for a government-backed stablecoin for residents while pioneering a $149 million digital bond in Q3 2025. Not keen on settling for local developments, Thailand is riding the wave of key regional partnerships to improve the state of payments in the Asia Pacific region. Watch: New age of payment solutions title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen=""> Asia Digital Wallet Indonesia Research and Markets Thailand
Yahoo
29-05-2025
- Business
- Yahoo
Research and Markets Launches Expert Network Service to Connect Clients with On-Demand Industry Expertise
Research and Markets, the world's largest market research store, is proud to announce the launch of its new Expert Network service. This offering connects clients directly with seasoned industry professionals, providing tailored insights to support strategic decision-making across over 800 sectors. Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- Research and Markets has been a trusted partner for organisations seeking authoritative market intelligence for more than two decades. The launch of the Expert Network represents a powerful new layer to its offerings; direct access to individuals who are actively shaping the sectors they work in, C-suite executives, and innovators bringing their firsthand perspectives to clients seeking actionable guidance. Key Features of the Expert Network Service: Direct access to industry professionals with deep expertise and real-world experience Customised consultations tailored to specific strategic needs, including go-to-market planning, research validation, and executive briefings Flexible formats including one-on-one calls, virtual sessions, and longer-term advisory engagements Global reach spanning multiple industries and geographic markets "Our mission has always been to empower clients with the insights they need to make confident, informed decisions,' said Cliff Sheridan, General Manager of Research and Markets. 'The launch of our Expert Network adds another layer to that, giving clients the ability to connect directly with experienced professionals who can help them apply that intelligence in practical, high-impact ways" The Expert Network service complements Research and Markets' extensive portfolio of market research reports, custom research services, conferences and training programs. By integrating expert consultations into its offerings, the company aims to provide a more holistic approach to market intelligence. For more information about the Expert Network service or to schedule a consultation, please visit About Research and Markets: Founded in 2002 and headquartered in Dublin, Ireland, Research and Markets has grown into the world's largest market research store, offering insights into over 800 industries. With a client base that includes more than 450 Fortune 500 companies, Research and Markets is dedicated to providing the highest quality market research and analysis to support strategic decision-making. CONTACT: Laura Wood, Senior Press Manager press@ For E.S.T. Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Wire
28-05-2025
- Business
- Business Wire
Research and Markets Launches Expert Network Service to Connect Clients with On-Demand Industry Expertise
DUBLIN--(BUSINESS WIRE)--Research and Markets, the world's largest market research store, is proud to announce the launch of its new Expert Network service. This offering connects clients directly with seasoned industry professionals, providing tailored insights to support strategic decision-making across over 800 sectors. Real-world insights. On-demand expertise. Strategic impact. Share Research and Markets has been a trusted partner for organisations seeking authoritative market intelligence for more than two decades. The launch of the Expert Network represents a powerful new layer to its offerings; direct access to individuals who are actively shaping the sectors they work in, C-suite executives, and innovators bringing their firsthand perspectives to clients seeking actionable guidance. Key Features of the Expert Network Service: Direct access to industry professionals with deep expertise and real-world experience Customised consultations tailored to specific strategic needs, including go-to-market planning, research validation, and executive briefings Flexible formats including one-on-one calls, virtual sessions, and longer-term advisory engagements Global reach spanning multiple industries and geographic markets "Our mission has always been to empower clients with the insights they need to make confident, informed decisions,' said Cliff Sheridan, General Manager of Research and Markets. 'The launch of our Expert Network adds another layer to that, giving clients the ability to connect directly with experienced professionals who can help them apply that intelligence in practical, high-impact ways." The Expert Network service complements Research and Markets' extensive portfolio of market research reports, custom research services, conferences and training programs. By integrating expert consultations into its offerings, the company aims to provide a more holistic approach to market intelligence. For more information about the Expert Network service or to schedule a consultation, please visit About Research and Markets: Founded in 2002 and headquartered in Dublin, Ireland, Research and Markets has grown into the world's largest market research store, offering insights into over 800 industries. With a client base that includes more than 450 Fortune 500 companies, Research and Markets is dedicated to providing the highest quality market research and analysis to support strategic decision-making.
Yahoo
27-05-2025
- Business
- Yahoo
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more. Two U.S. healthcare innovators, Hologic HOLX and Quest Diagnostics DGX, have established a strong foothold in this space, each with its own areas of specialization. Hologic, with a market cap of $12.10 billion, develops products and services across the women's healthcare continuum, such as advanced diagnostics products, medical imaging systems and surgical products. In comparison, Quest Diagnostics, with a market cap of $19.12 billion, provides a comprehensive portfolio of diagnostic tests for all stages of a woman's life — from routine screenings like cervical cancer and sexually transmitted infections (STIs) to pregnancy and fertility testing. Between these two, which one stands out as the smarter pick now? Let's dive deep into their fundamentals, growth drivers and challenges to find out. The Marlborough, MA-based company benefits from its strategy of building multiple durable growth drivers across all its global franchises. Key offerings include Aptima and Panther Fusion assays for sexually transmitted diseases (STDs), vaginitis and respiratory infections. The BV/CV/TV assay shows strong double-digit growth, supported by rising awareness and reimbursement in the U.S. vaginitis market. Molecular growth is further backed by the Biotheranostics business, driven by the rising adoption of the Breast Cancer Index test. However, weaker HIV testing in Africa due to federal funding cuts affected the fiscal 2025 second-quarter performance and is likely to persist. Hologic is seeing strong adoption of the Genius Digital Diagnostics System — the first FDA-cleared digital cytology system for cervical cancer screening, combining novel artificial intelligence (AI) with advanced imaging. However, Q2 International cytology and perinatal sales were impacted by South Korea's physician strike and reduced hospital spending in China. On the MedTech side, the company's mammography products continue to command leading market shares. In the second quarter, recurring service revenues (more than 45% of total Breast Health revenues) rose 12% year over year. The addition of Endomagnetics enhanced its Interventional Breast portfolio, with Hologic now selling its products directly through its U.S. salesforce to tap into wireless localization market opportunities. However, as anticipated, softer capital equipment sales caused the segment's revenues to decline 7.4%. Internationally, the Surgical business continues to be a standout. The company demonstrates sound financial health, with the flexibility to execute both tuck-in M&A and share repurchases. Still, macroeconomic challenges, including the ongoing trade war in China, have affected its 2025 outlook. Tariffs are expected to impact manufacturing costs by $20 million to $25 million per quarter, with two-thirds of it tied to imports from Costa Rica. Based in Secaucus, NJ, Quest Diagnostics is experiencing strong growth in Women's and Reproductive Health, one of its five key clinical areas where it offers Advanced Diagnostics. The growth is largely driven by prenatal and hereditary genetic testing over the past several quarters. In March 2025, the company launched a new solution that allows patients to self-collect a specimen for human papillomavirus (HPV) cervical cancer screening in a physician's office or other healthcare setting. The test uses Roche's RHHBY HPV self-collection solution and builds on Quest Diagnostics' STI-related self-collection option, introduced in October last year. Other clinical areas — advanced cardiometabolic, autoimmune, brain health and oncology — also posted double-digit growth in the first quarter of 2025, contributing to the 12% year-over-year revenue increase. Recent introductions include a laboratory-developed test to confirm Alzheimer's disease (AD) pathology in symptomatic patients and the Haystack MRD — its first circulating tumor DNA (ctDNA) minimal residual disease (MRD) test for assessing early risk of cancer recurrence. The company continues expanding the Advanced Diagnostics portfolio to enable growth across its core channels: Physicians, Hospitals and Consumers. In 2024, Quest Diagnostics completed eight acquisitions, including LifeLabs in Canada, and formed new health plan relationships. These favorably impacted both Q1 Diagnostic Information Services sales and adjusted operating income, translating to 8.3% growth in adjusted earnings per share (EPS). The company also became the first independent lab in the Optum Health preferred network. In February, Quest Diagnostics extended its chronic kidney disease test portfolio to include dialysis-related laboratory and water testing capabilities via a new agreement with Fresenius Medical Care FMS. Operationally, Quest Diagnostics is increasing the use of automation, robotics and AI across the business to drive productivity gains and improve user experience. The company teamed up with Google Cloud to streamline data management using generative AI. Despite broader economic pressures, Quest Diagnostics reaffirmed its 2025 revenue and adjusted EPS guidance. Yet, its escalating debt levels are a concern, ending the first quarter with $5.86 billion in long-term debt and just $188 million in cash and cash equivalents. The Zacks Consensus Estimate for Hologic's fiscal 2025 sales and EPS implies a year-over-year improvement of 1.2% and 3.2%, respectively. The bottom-line estimates have shown mixed movements in the last 30 days. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Image Source: Zacks Investment Research The Zacks Consensus Estimate for DGX's 2025 sales and EPS suggests a year-over-year improvement of 9.2% and 8.6%, respectively. Analysts seem more bullish on Quest Diagnostics, given the upward EPS estimate revisions in the last 30 days. Image Source: Zacks Investment Research In the past six months, Hologic's shares have plunged significantly, down 31.6%, while the benchmark S&P 500 slipped just 3.2%. In contrast, Quest Diagnostics held its ground with a 4.9% gain. Image Source: Zacks Investment Research Hologic is trading at a forward price-to-sales (P/S) multiple of 2.87X, higher than Quest Diagnostics' 1.75X P/S over the last five years. However, both HOLX and DGX appear discounted when compared to their respective industry averages of 4.04X and 2.71X. Each of them has a Value score of B. Image Source: Zacks Investment Research As a pure-play in women's health, Hologic continues to benefit from its diversified revenue model and growth drivers. International prospects are encouraging, while expanding into new areas through M&A activities instills optimism. While near-term headwinds from both internal and external pressures remain, the company's financial strength and a P/S below the industry suggest potential for long-term stability. For now, holding onto HOLX stock seems like a prudent choice. Meanwhile, Quest Diagnostics, as a clinical laboratory services company, sees strong growth opportunities in the women's and reproductive health space. Steady growth from Advanced Diagnostics and contributions from recent acquisitions are highly promising. Further, the stock's recent favorable performance, attractive valuation and upward analyst estimate revisions make it an equally compelling case to stay invested. HOLX and DGX each carry a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
26-05-2025
- Health
- Time of India
Pills, promotions and a dose of doubt: Influencers, VC money fuel India's booming supplements market
Live Events A decade ago, India's health supplements mostly meant vitamin C, iron and B12 tablets purchased at pharmacies after consulting a doctor. Fast forward to 2025, and a whole new market has emerged—gummies to enhance your hair health, powders to boost collagen, liquid for gut, pills for women's perimenopause hormonal imbalance, magnesium tablets for better sleep, testosterone boosters, capsules with calming properties and vegan versions of all supplement wave in the country was sparked by increased health awareness after the Covid-19 pandemic and powered by social media influencer marketing and a rush of venture capital (VC), according to industry executives and products are being sold directly to consumers on ecommerce websites as well as quick-commerce apps, spawning a fast-growing segment within the health sector. But as gummies and pills become lifestyle staples, the line between wellness and pseudoscience is blurring. Most items are sold over the counter—with no prescription, no pharmacist and often no clarity on whether they actually result? A shelf full of products that look similar, promise big results and raise a critical question—how much of it is science, and how much social media hype?India's nutritional supplement industry, pegged at $47.92 billion in 2024, is projected to expand to $68.43 billion by 2030, at a compound annual growth rate of 8.1%, according to market research firm Research and Markets. The growth story has attracted both founders and venture capitalists. 'Just after the Covid-19 pandemic, the evolution of these nutra products happened with immunity-building items. After seeing good acceptance from the audience and more usage of digital platforms (ecommerce and quick-commerce) to buy such products, brands started experimenting with their offerings,' said Renu Bisht, founder of Commercify360, a Gurgaon-based brand consulting funding numbers back this up. According to data firm Venture Intelligence, the sector raised more than $500 million between 2020 and May 2025. The latest in the line is Mumbai-based The Good Bug, a gut health startup that raised about $12 million in a round led by Susquehanna Asia Venture Capital, with Fireside Ventures Khaitan, principal at Fireside Ventures, emphasised the sharpening focus on science and research, along with innovation, in delivery formats. 'As themes like women's health, longevity and bone health evolve, we are looking to double down on startups operating at the intersection of unmet consumer needs and science-led innovation,' he health professionals are beginning to worry that the focus is shifting from effectiveness to aesthetics. 'The wellness sector is booming in India, which is why a lot of companies are getting a lot of VC funding early on. They use a lot of that funding to basically not work so much on the formulation but more on the marketability of a product,' said Poorvi Bhat Khandige, a Bengaluru-based naturopathic physician and nutritionist.'Health supplement brands are heavily reaching out to influencers because the concept is fairly new in India,' said Commercify 360's Bisht. 'Brands are partnering with health influencers, doctors and fitness trainers for marketing in order to build the audience's trust. Some brands are spending 15–30% of their budget on influencer marketing.'For example, nutrition brand Plix partners with Gen Z creators to reach urban, health-aware label Kapiva, from Kolkata-based Baidyanath, works with regional wellness influencers, while nutrition brand Fast&Up aligns with athletes and fitness content creators. 'We are trying to reach our target audience and continuously build awareness at the right frequency with them,' said Keshav Biyani, founder of gut health-focused brand The Good Unilever-backed Wellbeing Nutrition , a direct-to-consumer nutraceutical player, said 20-25% of its expenses are allocated to companies are ramping up their marketing budgets to build awareness by partnering with doctors and the marketing-first approach leads to many consumers buying the products without understanding them, and sometimes overusing them, leaving experts and nutritionists worried.'We've seen almost 200% growth month-on-month where protein is concerned, which is good and bad,' said Avnish Chhabria, founder of Wellbeing Nutrition. 'It's good, because everyone's gotten the sense and understanding of what they need to take. It's bad, because even people who are eating enough protein in a day are now overconsuming it, which could eventually lead to kidney problems.'The lack of guidance regarding the usage of such products poses a real risk. In some cases, certain ingredients require specific lifestyle choices to be instance, a Jaipur-based consumer used a popular nutrition brand's metabolically lean powder for more than a year before eventually stopping, after realising that some ingredients in the product required lifestyle adjustments. 'The product has EGCG and ALA (epigallocatechin gallate and alpha-lipoic acid are ingredients typically used in weight loss products), both of which can cause issues if you're not active,' the person said on condition of some products may fall short of their promises. Hair gummies, for example, are marketed with the promise of improving hair health and making it stronger and shinier. However, according to Khandige, a nutritionist, many of these products don't contain a sufficient therapeutic dose to be truly as the market expands, several leading brands are grappling with challenges tied to regulatory scrutiny, supply chain issues and shifting consumer expectations. GNC , a supplement retailer in the US—where the supplements market is projected to exceed $70 billion by 2031, from around $43 billion in 2022, according to data and business intelligence platform Statista—has faced multiple legal battles over product quality. Elysium Health, known for its anti-aging supplements, has drawn criticism from scientists, who have questioned the efficacy of its claims. However, the risk of such products reaching Indian consumers is heightened by the rise of fast and frictionless delivery channels such as quick-commerce supplement products in India fall under the purview of the Food Safety and Standards Authority of India, and not the drug regulator. That means weaker scrutiny and lighter penalties despite brands making bold claims like 'improves liver health' or 'reverses aging'.Health experts have long called for stringent oversight. Recently, an inter-ministerial committee headed by former health secretary Apurva Chandra recommended that any supplement claiming to treat or mitigate a disease should be classified as a drug. That would bring such products under the Central Drugs Standard Control Organisation and subject them to stricter regulation. Experts agree that until there is better education, regulation and transparency, consumers will largely have to navigate this booming market on their own—one Instagram ad at a time.
